ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-20

Study Completion Date

2023-04-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to evaluate the safety and treatment effects of fosgonimeton (ATH-1017) in subjects with Parkinson's Disease Dementia or Dementia with Lewy Bodies, with a randomized treatment duration of 26 weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants

NCT02337738

Parkinson's Disease

COMPLETED PHASE2/PHASE3

Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease

NCT04449484

Parkinson's Disease

COMPLETED PHASE1

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

NCT02847650

Parkinson Disease

TERMINATED PHASE2

SHARPEN - Parkinson's Disease Dementia

NCT05987540

Parkinson Disease Dementia

TERMINATED NA

A Study of E2007 In Patients With Parkinson's Disease

NCT00427011

Parkinson's Disease

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is designed to evaluate the safety and treatment effects of ATH-1017 in subjects with Parkinson's Disease Dementia or Dementia with Lewy Bodies, with a randomized, double-blind, placebo-controlled, parallel-arm treatment duration of 26 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease Dementia Dementia With Lewy Bodies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

40mg Dose

Daily subcutaneous injection of 40mg ATH-1017

Group Type EXPERIMENTAL

ATH-1017

Intervention Type DRUG

Daily subcutaneous injection of ATH-1017 in a pre-filled syringe

70mg Dose

Daily subcutaneous injection of 70mg ATH-1017

Group Type EXPERIMENTAL

ATH-1017

Intervention Type DRUG

Daily subcutaneous injection of ATH-1017 in a pre-filled syringe

Placebo

Daily subcutaneous injection of Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Daily subcutaneous injection of Placebo in a pre-filled syringe

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ATH-1017

Daily subcutaneous injection of ATH-1017 in a pre-filled syringe

Intervention Type DRUG

Placebo

Daily subcutaneous injection of Placebo in a pre-filled syringe

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects with confirmed diagnosis of Parkinson's disease or Dementia with Lewy Bodies
* MoCA score 11 to 23, inclusive, at screening
* Probable Parkinson's Disease Dementia or Lewy Body Dementia
* BMI between ≥ 16and ≤ 35 kg/m2 for females and between≥ 18 and ≤ 35 kg/m2 for males at Screening
* Reliable and capable support person/caregiver, who is willing to accept responsibility for supervising the treatment or, if required, administering study drug, and assessing the condition of the subject throughout the study in accordance with all protocol requirements

Exclusion Criteria

* Hoehn-Yahr stage 5
* History of significant neurological disease other than PDD or DLB that may affect cognition at onset of dementia
* Subjects on deep brain stimulation
* History of brain MRI scan indicative of any other significant abnormality
* History of unexplained loss of consciousness, and epileptic fits
* Hearing test result considered unacceptable for auditory ERP P300 assessment
* Diagnosis of severe major depressive disorder even without psychotic features (GDS score \[15-item scale\] \>7 at Screening)
* Significant suicide risk based on C-SSRS
* Significant psychosis (according to Diagnostic and Statistical Manual of Mental Disorders)
* Moderate or severe substance abuse disorder (according to DSM-5)
* Myocardial infarction or unstable angina within the last 6 months
* Clinically significant cardiac arrhythmia (including atrial fibrillation), cardiomyopathy, or cardiac conduction defect (note: pacemaker is acceptable)
* Clinically significant ECG abnormality at Screening
* Chronic kidney disease (eGFR \< 45 mL/min using Cockcroft-Gault formula)
* Hepatic impairment with alanine aminotransferase or aspartate aminotransferase \> 2 times the upper limit of normal, or Child-Pugh class B and C
* Malignant tumor within 3 years before Screening
* Memantine at any dose or combination
* Donepezil at 23 mg

Minimum Eligible Age

40 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No